News

July 17, 2018

FDA OKs Adagene’s ADG-106 for Clinical Trial in Solid Tumors, Non-Hodgkin’s Lymphoma

News

Adagene soon will initiate a Phase 1 clinical trial testing its lead product, ADG-106, in patients who have advanced solid tumors and non-Hodgkin’s lymphoma, the company announced. This follows the U.S. ... Read more

July 11, 2018July 11, 2018

Health Canada OKs Gazyva as First-line Therapy for Advanced Follicular Lymphoma

News

Patients in Canada who have advanced follicular lymphoma now can receive Gazyva (obinutuzumab) in combination with chemotherapy as first-line therapy, Roche Canada announced. Health Canada’s decision follows Gazyva’s approval in the ... Read more

July 10, 2018

Lymphoma Therapies Kymriah, Yescarta Recommended for Approval in Europe

News

The European Medicines Agency (EMA) has recommended the approval of two lymphoma medications: Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel). The EMA’s decision represents the first two recommendations for chimeric antigen receptors ... Read more

July 9, 2018

Sintilimab Safe, Effective for Relapsed or Refractory Hodgkin’s Lymphoma Patients, Phase 2 Trial Shows

News

Sintilimab (IBI308), an immunotherapy candidate, was found to be safe and completely eliminated tumors in one-fourth of Chinese patients with relapsed or refractory classical Hodgkin’s lymphoma (cHL) treated in a Phase 2 ... Read more

July 5, 2018

Six-gene Signature Predicts Survival in Mantle Cell Lymphoma Patients, Study Reports

News

A six-gene signature related to B-cell activity can predict survival in patients with mantle cell lymphoma (MCL), a study suggests. Conducted by researchers in Italy, the study, “A B-Cell Receptor-Related ... Read more

July 3, 2018

FDA Names CPI-613, Potential Treatment for Burkitt’s Lymphoma, an Orphan Drug

News

The U.S. Food and Drug Administration has again designated Rafael Pharmaceuticals’ lead candidate CPI-613 an orphan drug, this time to further advance it in clinical trials as a potential treatment for Burkitt’s lymphoma. ... Read more

July 2, 2018

Umbralisib Linked to Fewer Side Effects in Advanced Lymphoma and Leukemia Patients, Data Show

News

Umbralisib, an inhibitor of the PI3K delta protein, has a better long-term safety profile than equivalent treatments for advanced leukemia and lymphoma patients, those whose cancer failed to respond to multiple therapy ... Read more

June 29, 2018

New Biosensor Sheds Light on Behavior of Individual Cancer Cells, Study Reports

News

A newly developed biosensor that harnesses the power of nanophotonics is able to detect the secretion of cytokines — small inflammatory molecules that play important roles in cancer — from ... Read more

June 27, 2018

Keytruda-AFM13 Combo Effective for Hodgkin’s Lymphoma, Preliminary Phase 1b Data Show

News

Treatment with Keytruda (pembrolizumab) and Affimed’s AFM13 is well-tolerated with a favorable response rate in patients with relapsed or refractory Hodgkin’s lymphoma, according to an early analysis of a Phase 1b trial. ... Read more

June 26, 2018

Venclexta-Rituxan Combo Extends Undetectable Disease in CLL, Study Finds

News

A combination of Venclexta (venetoclax) plus Rituxan (rituximab) was better than standard of care at extending the duration of undetectable residual disease in patients with relapsed or refractory chronic lymphocytic ... Read more